Low-Intensity International Normalized Ratio (INR) Oral Anticoagulant Therapy in Chinese Patients with Mechanical Heart Valve Prostheses

Cell Biochemistry and Biophysics

Volumn 62, Issue 1, 2012, Pages 147-151

  Haibo, Zhang ^a   Jinzhong, Li ^a   Yan, Liu ^a   Xu, Meng ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Anticoagulant; Complication; Heart valve prostheses; International normalized radio; Mortality

Indexed keywords

ANTICOAGULANT AGENT; WARFARIN;

ADULT; ARTICLE; BLEEDING; CHEMICALLY INDUCED DISORDER; CHINA; FEMALE; FOLLOW UP; HEART VALVE REPLACEMENT; HUMAN; INCIDENCE; INTERNATIONAL NORMALIZED RATIO; MALE; MIDDLE AGED; ORAL DRUG ADMINISTRATION; THROMBOEMBOLISM;

ADMINISTRATION, ORAL; ADULT; ANTICOAGULANTS; CHINA; FEMALE; FOLLOW-UP STUDIES; HEART VALVE PROSTHESIS IMPLANTATION; HEMORRHAGE; HUMANS; INCIDENCE; INTERNATIONAL NORMALIZED RATIO; MALE; MIDDLE AGED; THROMBOEMBOLISM; WARFARIN;

EID: 84855584927     PISSN: 10859195     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12013-011-9275-4     Document Type: Article

References (18)

1. Liu, Y., Meng, X., & Chen, B. (2001). Clinical results of the low intensity of oral anticoagulant therapy for patients with mechanical heart valve prostheses. Chinese Journal of Thoracic and Cardiovascular Surgery, 17, 163-265.
2. Acar, J., Iung, B., Boissel, J. P., Samama, M. M., Michel, P. L., Teppe, J. P., et al. (1996). AREVA: Multicenter randomized comparison of low-dose versus standard-dose anticoagulation in patients with mechanical prosthetic heart valves. Circulation, 94, 2107-2112.
3. Kayali, M. T., Fetieh, M. W., Abdulsalam, M. A., Memon, F., Moinuddin, M., & Raffa, H. (1998). Thrombotic obstruction of bileaflet mechanical prosthetic heart valves: Early diagnosis and management. The Journal of Cardiovascular Surgery (Torino), 39, 331-335.
4. Kalaria, V. G., Passannante, M. R., Shah, T., Modi, K., & Weisse, A. B. (1998). Effect of mitral regurgitation on left ventricular thrombus formation in dilated cardiomyopathy. American Heart Journal, 135, 215-220.
5. Israel, D. H., Sharma, S. K., & Fuster, V. (1994). Antithrombotic therapy in prosthetic heart valve replacement. American Heart Journal, 127, 400-411.
6. Kontozis, L., Skudicky, D., Hopley, M. J., & Sareli, P. (1998). Long-term follow-up of St. Jude medical prosthesis in a young rheumatic population using low-level warfarin anticoagulation: An analysis of the temporal distribution of causes of death. American Journal of Cardiology, 81, 736-739.
7. Salem, D. N., Stein, P. D., Al-Ahmad, A., Bussey, H. I., Horstkotte, D., Miller, N., et al. (2004). Antithrombotic therapy in valvular heart disease-native and prosthetic: The seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest, 126, 457S-482S.
8. You, J. H., Chan, F. W., Wong, R. S., & Cheng, G. (2005). Is INR between 2. 0 and 3. 0 the optimal level for Chinese patients on warfarin therapy for moderate-intensity anticoagulation? British Journal of Clinical Pharmacology, 59, 582-587.
9. Kudo, T., Kawase, M., Kawada, S., Kurosawa, H., Koyanagi, H., Takeuchi, Y., et al. (1999). Anticoagulation after valve replacement: A multicenter retrospective study. Artificial Organs, 23, 199-203.
10. Hirsh, J. (1992). Oral anticoagulant therapy. Urgent need for standardization. Circulation, 86, 1332-1335.
11. Gohlke-Barwolf, C., Acar, J., Burckhardt, D., Oakley, C., Butchart, E., Krayenbuhl, P., et al. (1993). Guidelines for prevention of thromboembolic events in valvular heart disease. Ad Hoc committee of the working group on valvular heart disease, European society of cardiology. Journal of Heart Valve Disease, 2, 398-410.
12. Cannegieter, S. C., Rosendaal, F. R., Wintzen, A. R., van der Meer, F. J., Vandenbroucke, J. P., & Briet, E. (1995). Optimal oral anticoagulant therapy in patients with mechanical heart valves. New England Journal of Medicine, 333, 11-17.
13. Eberlein, U., von der, E. J., Rein, J., & Esperer, H. D. (1990). Thromboembolic and bleeding complications after mitral valve replacement. European Journal of Cardio-Thoracic Surgery, 4, 605-612.
14. Horstkotte, D., Schulte, H. D., Bircks, W., & Strauer, B. E. (1994). Lower intensity anticoagulation therapy results in lower complication rates with the St. Jude medical prosthesis. Journal of Thoracic and Cardiovascular Surgery, 107, 1136-1145.
15. Koertke, H., Zittermann, A., Wagner, O., Ennker, J., Saggau, W., Sack, F. U., et al. (2010). Efficacy and safety of very low-dose self-management of oral anticoagulation in patients with mechanical heart valve replacement. Annals of Thoracic Surgery, 90, 1487-1493.
16. Xu, Z., Zhang, B., Zhu, J., et al. (1995). Ten year follow-up of national home-made mitral mechanical valve replacement. Chinese Journal of Thoracic Cardiovascular Surgery, 11, 135.
17. Tang, B., Tong, C., Zhang, X., et al. (2004). Clinical research of international normalized ratio monitoring after mechanical heart valve replacement. Journal of Sun Yat-sen University of Medical Sciences, 19, 568-572.
18. Debetaz, L. F., Ruchat, P., Hurni, M., Fischer, A., Stumpe, F., Sadeghi, H., et al. (1997). St. Jude medical valve prosthesis: An analysis of long-term outcome and prognostic factors. Journal of Thoracic and Cardiovascular Surgery, 113, 134-148.